Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hip Replacement System (HRS-P) in Primary Total Hip Arthroplasty ((HRS-P))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02836262
Recruitment Status : Recruiting
First Posted : July 18, 2016
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Hip Innovation Technology

Brief Summary:
To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.

Condition or disease Intervention/treatment Phase
Osteoarthritis of Hip Device: HIT Hip Replacement System Not Applicable

Detailed Description:

The HIT Hip Replacement System (HHRS) is a Metal-on-Polyethylene (MoP) conventional hip prosthesis. The HHRS consists of a femoral stem, an acetabular cup and a Cobalt Chromium Molybdenum (CoCrMo) ball that articulates within a polyethylene liner. The ball sits on the acetabular cup, and the polyethylene liner is attached to the femoral cup, which attaches to the femoral stem, instead of the acetabular cup. The acetabular component of the HHRS consists of a hemispherical acetabular shell with a clustered screw-hole design. The outside of the shells are coated with titanium plasma to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The acetabular cup has a 3-hole design that accommodates three titanium alloy bone screws. Inside the acetabular cup is a male taper for assembly with the acetabular ball. The femoral component consists of a femoral stem manufactured from titanium and a mating cobalt chrome femoral cup lined with a highly cross-linked ultra-high-molecular-weight polyethylene (UHMWPE). As with the acetabular cup, the femoral stem is porous coated using a plasma spray of pure titanium, which is intended to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The femoral stem incorporates a female taper for assembly with the male taper of the femoral cup.

The device has undergone extensive pre-clinical testing. There is no clinical experience with the HRS.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Prospective Study of the Hip Innovation Technology (HIT) Hip Replacement System in Primary Total Hip Arthroplasty
Actual Study Start Date : August 25, 2017
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HIT Hip Replacement System (HRS)
Single group assignment with historical controls.
Device: HIT Hip Replacement System
HIT Hip Replacement System




Primary Outcome Measures :
  1. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) v3.0 Likert Scale Functional Limitations Score between baseline (pre-operative) and the 730- day post-operative follow-up time point. [ Time Frame: between pre-operative and 730 days (24 months) ]
  2. Change in Harris Hip Score between baseline (pre-operative) and the 730-day post-operative follow-up time point. [ Time Frame: between pre-operative and 730 days (24 months) ]

Secondary Outcome Measures :
  1. Change in Oxford Hip Score between 730-day post-operative and baseline (pre-surgery) [ Time Frame: between 730-days post-operative and baseline (pre-surgery) ]
  2. Change in Short Form 36 v2 Physical Component Score (PCS) between 730-days post-operative and baseline (pre-surgery) [ Time Frame: between 730-days post-operative and baseline (pre-surgery) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 79 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement.
  • Age between 65 and 79 years (inclusive) at the time of enrollment.
  • Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator.
  • Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst)
  • Signed and dated informed consent document.
  • Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires.

Exclusion Criteria:

  • Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months;
  • Patient has planned total hip arthroplasty on a contra-lateral joint in the next 12 months;
  • Patient has a known allergy to any component of the study device;
  • Patient has a history of active sepsis in the joint;
  • Patient has an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible;
  • Patient has total or partial absence of the muscular or ligamentous apparatus;
  • Patient has known moderate to severe renal insufficiency;
  • Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's discretion);
  • Patient has a deformity of the affected limb or significant anatomic variance of the affected hip;
  • Patient has an active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study;
  • Patient has any condition which may, in the opinion of the Investigator, interfere with the total hip replacement survival or patient outcomes (e.g. Paget's disease, Charcot's disease);
  • Patient has rheumatoid arthritis or other autoimmune condition that affect joints (e.g. Lupus Arthritis);
  • Patient has any condition that would interfere with patient self-assessment or pain, the function or quality of life required for patient reported outcomes during the study (based on the Investigator's discretion);
  • Body Mass Index (BMI) of 40 or more;
  • Patient has an active infection (e.g. hepatitis, AIDS, ARC) - systemic or at the site of intended surgery;
  • Patient is currently participating in any investigational study not related to this study's pre-operative or post-operative care;
  • Patient has any other severe acute or chronic medical condition that may interfere with the interpretation of the study results, in the judgment of the Investigator, which would make the patient inappropriate for entry into this study;
  • Patient has a history of metabolic bone disease (e.g. Paget's disease or osteomalacia);
  • Patient is currently pregnant or is planning to become pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836262


Contacts
Layout table for location contacts
Contact: Linda Braddon, PhD 770-837-2681 LGB@SecureBME.com
Contact: Thomas Turgeon, MD 204-926-1218 tturgeon@cjrg.ca

Locations
Layout table for location information
Canada, Manitoba
Orthopaedic Innovation Centre Recruiting
Winnipeg, Manitoba, Canada, R2K 2M9
Contact: Thomas Turgeon, MD    (204) 926-1218    tturgeon@cjrg.ca   
Contact: Sarah Tran    (204) 926-1231    stran@orthoinno.com   
Principal Investigator: Thomas Turgeon, MD         
Sponsors and Collaborators
Hip Innovation Technology
Investigators
Layout table for investigator information
Principal Investigator: Thomas Turgeon, MD Orthopaedic Innovation Centre
Study Director: Branko Kopjar, MD, PhD Nor Consult, LLC

Layout table for additonal information
Responsible Party: Hip Innovation Technology
ClinicalTrials.gov Identifier: NCT02836262     History of Changes
Other Study ID Numbers: HIT-001
First Posted: July 18, 2016    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Hip
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases